Cohance Lifesciences: FDA rates Telangana plant as VAI after inspection
The FDA has finished its inspection of Cohance Lifesciences' Shamshabad plant and classed it as Voluntary Action Indicated, the company said.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The US Food and Drug Administration has completed its inspection of Cohance Lifesciences Ltd's formulation manufacturing plant in Shamshabad, Telangana. The facility was classed as Voluntary Action Indicated (VAI). The company announced this on November 21, according to TradingView, and had earlier notified exchanges about the inspection on September 5, 2026. The regulator also issued an Establishment Inspection Report (EIR) for the site.
According to the FDA's definition, a VAI rating means regulatory action is not currently warranted, but the review found problems the plant should fix voluntarily. In a regulatory filing, the company said: "With the receipt of the EIR, the said inspection stands concluded." Cohance shares closed at ₹462.30 on the NSE on Friday, November 20, up 0.62% on the day.
why it matters
For investors, the key point is that the inspection ended without enforcement measures. For drugmakers that supply the US market, this reduces uncertainty, though the plant still has to address the observations. The news concerns one company and is unlikely to move the broader market.
market impact
Cohance Lifesciences shares: the closed inspection without enforcement action reduces regulatory uncertainty
- Cohance Lifesciences shares pressure up — regulatory action is not warranted and the inspection is closed
tags
instruments
sources
- Cohance Lifesciences: USFDA inspects and classifies Telangana facility as ‘voluntary action indicated’ — TradingView, 21 November 2026 at 10:01 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗